-
Axcella Health NASDAQ:AXLA Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company's product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella's pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.
Location: | Website: www.axcellahealth.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
7.33%
Insider Ownership
15.80%
Institutional Own.
55.80%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AXA1125 Details COVID-19 | Phase 2/3 Initiation | |
AXA1125 Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease | Failed Discontinued | |
AXA1665 Details Liver disease, Overt hepatic encephalopathy | Failed Discontinued |